Showing results (361-370 of 1,523) with videos related to
Sort By:
Pageof 153
CPT: Pharmacometrics & Systems Pharmacology|September 2, 2026
A Practical Alternative to Refine the Estimate of fmCYP3A4 and Evaluate Drug-Drug Interaction Potential for Ziftomenib Using PBPK Modeling to Inform LabelingIan E Templeton, Chara Litou, Hannah M Jones, et al.CPT: Pharmacometrics & Systems Pharmacology|December 13, 2022
Semimechanistic modeling of copeptin and aldosterone kinetics and dynamics in response to rehydration treatment for diabetic ketoacidosis in childrenMarije E Otto, Marie-Anne Burckhardt, Gabor Szinnai, et al.CPT: Pharmacometrics & Systems Pharmacology|June 28, 2022
A model-based meta-analysis of immune-related adverse events during immune checkpoint inhibitors treatment for NSCLCRenwei Zhang, Daming Kong, Rong Chen, et al.CPT: Pharmacometrics & Systems Pharmacology|October 8, 2020
Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3AYukio Otsuka, Mary P Choules, Peter L Bonate, et al.CPT: Pharmacometrics & Systems Pharmacology|October 13, 2020
Physiologically-Based Pharmacokinetic Modelling of Creatinine-Drug Interactions in the Chronic Kidney Disease PopulationHiroyuki Takita, Daniel Scotcher, Rajkumar Chinnadurai, et al.CPT: Pharmacometrics & Systems Pharmacology|January 21, 2020
gQSPSim: A SimBiology-Based GUI for Standardized QSP Model Development and ApplicationIraj Hosseini, Justin Feigelman, Anita Gajjala, et al.CPT: Pharmacometrics & Systems Pharmacology|January 21, 2020
Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell TransplantationJurgen B Langenhorst, Thomas P C Dorlo, Charlotte van Kesteren, et al.CPT: Pharmacometrics & Systems Pharmacology|May 27, 2021
Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancerHiroyuki Sayama, Diana Marcantonio, Takeyuki Nagashima, et al.CPT: Pharmacometrics & Systems Pharmacology|October 5, 2020
Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case StudyAna-Marija Grisic, Akash Khandelwal, Mauro Bertolino, et al.CPT: Pharmacometrics & Systems Pharmacology|January 29, 2020
Tumor Time-Course Predicts Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow-Up TimeIda Netterberg, René Bruno, Ya-Chi Chen, et al.Pageof 153